e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
Galanis Ilias, Lindstrand Ann, Darenberg Jessica, Browall Sarah, Nannapaneni Priyanka, Sjöström Karin, Morfeldt Eva, Naucler Pontus, Blennow Margareta, Örtqvist Åke, Henriques-Normark Birgitta
Source:
Eur Respir J 2016; 47: 1208-1218
Journal Issue:
April
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Galanis Ilias, Lindstrand Ann, Darenberg Jessica, Browall Sarah, Nannapaneni Priyanka, Sjöström Karin, Morfeldt Eva, Naucler Pontus, Blennow Margareta, Örtqvist Åke, Henriques-Normark Birgitta. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J 2016; 47: 1208-1218
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
ERS short guidelines on COVID-19 management
Influenza vaccination: protecting the most vulnerable
Understanding new vaccines for SARS-CoV-2 and their regulation
Related content which might interest you:
Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
The remaining challenges of pneumococcal disease in adults
Source: Eur Respir Rev 2012; 21: 57-65
Year: 2012
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Year: 2015
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Source: Eur Respir J 2015; 46: 1407-1416
Year: 2015
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population
Source: Eur Respir J 2016; 48: 1492-1496
Year: 2016
Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia
Source: Eur Respir J 2004; 24: Suppl. 48, 363s
Year: 2004
Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany
Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021
Year: 2022
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
Dynamics of serotypic composition of nasopharyngeal pneumococcal isolates in children pneumococcal nasopharyngeal colonization after the introduction of the vaccination program in Moscow
Source: Virtual Congress 2020 – Different aspects of paediatric viral and bacterial lung infections
Year: 2020
Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types
Source: Eur Respir J 2014; 44: 1646-1657
Year: 2014
Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough.
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021
Compliance with the pneumococcal and influenza vaccination recommendations in patients with COPD in Catalonia (Spain)
Source: Eur Respir J 2005; 26: Suppl. 49, 594s
Year: 2005
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
Source: Eur Respir J 2005; 26: 1086-1091
Year: 2005
Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV)
Source: Eur Respir J 2005; 26: Suppl. 49, 286s
Year: 2005
Serotype dynamics in pneumococcal diseases and the performance of vaccination strategies for older adults in germany
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept